lithium has been researched along with Tauopathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colton, CA; Everhart, A; Sudduth, TL; Wilcock, DM; Wilson, JG | 1 |
| Loy, R; Tariot, PN | 1 |
| Bhat, R; Burns, M; Dickson, D; Duff, K; Feinstein, B; Gaynor, K; Krishnamurthy, P; LaFrancois, J; Lewis, J; Meyerson, J; Noble, W; Olm, V; Planel, E; Suleman, F; Wang, L; Wen, Y; Zehr, C | 1 |
| Hamamura, T; Ishihara, T; Kugo, A; Kuroda, S; Lee, VM; Nakashima, H; Oshima, E; Suguimoto, P; Terada, S; Trojanowski, JQ; Yokota, O | 1 |
| Borghgraef, P; Croes, S; Devijver, H; Dewachter, I; Jaworski, T; Kremer, A; Muyllaert, D; Van Leuven, F | 1 |
1 review(s) available for lithium and Tauopathies
| Article | Year |
|---|---|
Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
Topics: Alzheimer Disease; Amyloid; Animals; Disease Models, Animal; Glycogen Synthase Kinase 3; Humans; Isoenzymes; Lithium; Mice; Mice, Transgenic; Phosphorylation; tau Proteins; Tauopathies | 2008 |
4 other study(ies) available for lithium and Tauopathies
| Article | Year |
|---|---|
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Humans; Inflammation; Learning; Lithium; Memory; Mice; Mice, Knockout; Mice, Transgenic; Nitric Oxide Synthase Type II; Phosphorylation; tau Proteins; Tauopathies; Treatment Outcome | 2012 |
Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
Topics: Alzheimer Disease; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium; Mice; Neuroprotective Agents; Phosphorylation; Research Design; Tauopathies; Valproic Acid | 2002 |
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Topics: Animals; Disease Progression; Enzyme Inhibitors; Epitopes; Glycogen Synthase Kinase 3; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Lithium; Lithium Chloride; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Phosphorylation; tau Proteins; Tauopathies | 2005 |
Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Glycogen Synthase Kinase 3; Humans; Immunohistochemistry; Lithium; Mice; Mice, Transgenic; Microscopy, Confocal; Phosphorylation; tau Proteins; Tauopathies; Time Factors; Ubiquitin | 2005 |